Graft-Versus-Host Disease (GVHD) Market Forecast to 2028 - Covid-19 Impact and Global Analysis - By Product Type ( Corticosteroids, ATG therapies, IL2Rα (CD25) inhibitors, TNFα inhibitors, Calcineurin inhibitors, mTOR inhibitors, SOT therapies, Anti-neoplastic therapies, Stem Cell Treatments, Extracorporeal Photophoresis, Other biologics ); Treatment Type ( Prophylaxis GVHD, Chronic GVHD, Acute GVHD ); End User ( Hospital Pharmacies, Retail Pharmacies, Online Pharmacies ) and Geography
Request Now
MARKET INTRODUCTION
Graft-versus-host disease (GVHD) is a medical condition which occurs after transplant surgeries where the immune cells from the donor attack on the recipient's organ tissues. This condition is a common side effect that is observed after an allogeneic bone marrow transplant (stem cell transplant). The symptoms of the disease can be from mild to severe and life-threatening and often causes diseases like jaundice, skin inflammation and others.
MARKET DYNAMICS
The graft-versus-host disease (GVHD) market is anticipated to grow in the forecast, owing increasing demand for bone marrow transplants, rising prevalence of cancer and increasing allogeneic hematopoietic stem cell transplant. In addition, growing awareness for cellular therapies is expected to offer significant growth opportunities in the market during the forecast period.
MARKET SCOPE
The "Graft-Versus-Host Disease (GVHD) Market Analysis to 2028" is a specialized and in-depth study of the biotechnology industry with a special focus on the global market trend analysis. The report aims to provide an overview of Graft-Versus-Host Disease (GVHD) market with detailed market segmentation by product type, treatment type, end user and geography. The Graft-Versus-Host Disease (GVHD) market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading Graft-Versus-Host Disease (GVHD) market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The graft-versus-host disease (GVHD) market is segmented on the basis of product type, treatment type, and end user. Based on product type the market is segmented as corticosteroids, ATG therapies, IL2Rα (CD25) inhibitors, TNFα inhibitors, Calcineurin inhibitors, mTOR inhibitors, SOT therapies, anti-neoplastic therapies, stem cell treatments, extracorporeal photophoresis and other biologics. On the basis of treatment type the market is segmented into prophylaxis GVHD, chronic GVHD, acute GVHD. The end user segment is classified into hospital pharmacies, retail pharmacies, and online pharmacies.
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the graft-versus-host disease (GVHD) market based on various segments. It also provides market size and forecast estimates from year 2020 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The graft-versus-host disease (GVHD) market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting graft-versus-host disease (GVHD) market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the graft-versus-host disease (GVHD) market in these regions.
The report covers key developments in the graft-versus-host disease (GVHD) market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from graft-versus-host disease (GVHD) market are anticipated to have lucrative growth opportunities in the future with the rising demand for graft-versus-host disease (GVHD) market in the global market. Below mentioned is the list of few companies engaged in the graft-versus-host disease (GVHD) market.
The report also includes the profiles of key graft-versus-host disease (GVHD) market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- Novartis AG
- BristolMyers Squibb
- Pfizer
- F. HoffmannLa Roche
- AbbVie
- Astellas Pharma
- Merck & Co
- Takeda Pharmaceutical
- Abbott
- Eli Lilly.
The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.
